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Introduction: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic
potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies
in the homologous recombination repair (HRR) pathway. Histone deacetylases (HDACs) are important for enabling
functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of
HRR-directed sub-nuclear foci. Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating
cancer by inhibiting DNA repair. Based on this, HDAC inhibition could be predicted to enhance the anti-tumor
effect of PARP inhibitors in cancer cells by blocking the HRR pathway.
Methods: We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance
the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western
blotting. We evaluated how exposure to SAHA affects the expression of HRR-associated genes. The accumulation of
DNA double strand breaks (DSBs) induced by combination treatment was assessed. Induction of autophagy was
monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3)
expression following co-treatment with olaparib and SAHA. These in vitro data were validated in vivo using a
human breast cancer xenograft model.
Results: Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC
inhibitors. Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed
functional Phosphatase and tensin homolog (PTEN). This effect was associated with down-regulation of the proliferative
signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage. The combined
anti-tumor effect of olaparib and SAHA was also observed in a xenograft model. These data suggest that PTEN
expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro
and in vivo.
Conclusion: Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC
patients that would favorably respond to a combination of olaparib with SAHA. This provides a strong rationale for
treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.* Correspondence: moisa@snu.ac.kr
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Breast cancer is a disease with a number of diverse mor-
phological subtypes. Invasive ductal carcinoma is the
most common morphologic subtype representing 80% of
invasive breast cancer cases [1]. In addition, it can be
subclassified into three major categories according to
different expression levels of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2) [2]. In general, hor-
mone receptor-positive breast cancer subtypes are less
progressive and amenable to hormone therapy. Although
HER2+ breast cancer subtype shows rapid progression,
targeted therapy for treating breast cancers over-
expressing HER2 has improved survival for HER2+
breast cancer patients [3]. In contrast to these two sub-
types, triple-negative breast cancer (TNBC) is resistant
to various chemotherapy agents and targeted drugs
because a widely available target for this subtype has not
yet been discovered. Therefore, the development of new
combined targeted therapy and identification of bio-
markers that can help predict responses to treatment are
still major challenges in TNBC.
Recent progress in the field of DNA repair has demon-
strated that a synthetic lethal approach involving the use
of poly (ADP-ribose) polymerase (PARP) inhibitors is a
promising new therapeutic strategy for treating various
cancers. DNA repair inhibitors have been shown to work
as single agents in patients with DNA repair-defective
tumors [4,5]. The most notable example so far is the use
of PARP inhibitors to treat individuals with inherited
breast and ovarian cancers lacking wild-type copies of
the BRCA1 and BRCA2 genes [6-8]. PARP inhibitors
have also produced promising results in TNBC patients
harboring BRCA-like genotypes or so-called BRCAness
[9]. Therefore, development of strategies for using PARP
inhibitors and selecting populations within TNBC that
will respond favorably to PARP inhibitor treatment
based on predictive biomarkers represents both a chal-
lenge and an opportunity for breast cancer research.
Additionally, enzyme-mediated DNA repair can cause
resistance to DNA-damaging anticancer drugs and radi-
ation, and inhibition of DNA repair may be therapeutic-
ally beneficial. In particular, it has been observed that
combining chemotherapy or radiotherapy with PARP in-
hibitors kills human cancer cells more effectively than a
genotoxic agent alone [8,10]. The development of new
therapies including molecular targeting agents is eagerly
awaited as well as treatment strategies to overcome che-
moresistance using PARP inhibitors that are effective for
ameliorating TNBC.
During the past few years, histone deacetylases
(HDACs) have garnered great interest as anticancer
therapeutic targets. Experimental data have suggested
that HDACs are involved in mammary tumorigenesis atmultiple levels [11,12]. HDACs participate in the nega-
tive regulation of genes such as ones encoding cell cycle
inhibitors, differentiation factors, and pro-apoptotic fac-
tors. In addition, the expression of genes associated with
angiogenesis along with cell invasion and migration are
enhanced by HDACs. Thus, HDACs play important
roles in cancer development by regulating the expression
of numerous genes involved in both cancer initiation
and progression. Based on the role of HDACs in cancer
development, HDAC inhibition could have potent anti-
tumor effects on various types of cancer by affecting
tumor cells at multiple levels. More specifically, inhib-
ition by HDACs could induce cell cycle arrest, apoptosis,
and differentiation while inhibiting angiogenesis along
with cell migration and invasion [12].
HDACs also enable functional HRR by regulating the
expression of homologous recombination repair (HRR)-
related genes and promoting the accurate assembly of
HRR-directed sub-nuclear foci [13,14]. There is evidence
showing that dysfunctional HDACs lead to the downreg-
ulated expression of DNA repair genes including RAD51
and BRCA1/2, resulting in defective DNA repair which
can result in the accumulation of DNA damage [14,15].
HDAC inhibitors have thus emerged recently as a class
of anticancer therapeutic agents that prevent DNA re-
pair. HDAC inhibition sustains DNA damage signaling
and suppresses DNA repair gene expression, which can
increase the sensitivity of cells to DNA damaging agents
similar to BRCA deficiency in breast cancer. For this
reason, HDAC inhibition could enhance the anti-tumor
effect of PARP inhibitors in cases of TNBC by blocking
the DNA repair pathway. Previous studies have shown
that HDAC inhibition does enhance cellular sensitivity
to DNA damaging agents; however, specific markers that
can help predict the combinational effect have not yet
been identified [16-18].
In the present investigation, we identified a determin-
ant of the combined effects of a PARP inhibitor with an
HDAC inhibitor in TNBC cell lines. We evaluated one
possible combined strategy to treat the TNBC subtype.
We discovered that suberoylanilide hydroxamic acid
(SAHA), a pan-HDAC inhibitor, enhanced the growth
inhibitory activities of olaparib, a PARP inhibitor, in
TNBC cells. Additionally, the combination of olaparib
plus SAHA induced the accumulation of DNA DSBs
and downregulated signal transduction in TNBC cells
that expressed phosphatase and tensin homolog (PTEN).
Our results suggest that the expression of PTEN in
TNBC cells significantly increased the anti-tumor effects
of olaparib and SAHA through the induction of both
apoptotic and autophagic cell death. Using a xenograft
mouse model of TNBC cells expressing PTEN, we veri-
fied that co-treatment with olaparib and SAHA inhibited
tumor growth. Taken together, these data suggest that
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gistic effect on TNBC cells that is associated with in-
creased levels of both apoptosis and autophagy regulated
by PTEN. More importantly, our results provide a ra-
tionale for conducting future clinical trials evaluating
the effectiveness of using olaparib combined with SAHA
to treat TNBC patients.
Methods
Reagents
Olaparib was provided by AstraZeneca (Macclesfield,
UK) and SAHA was purchased from Selleck (Houston,
TX, USA). Both reagents were dissolved in dimethyl
sulfoxide (DMSO) as 10 mmol/L stock solutions.
Cell lines and culturing
Human breast cancer cells (MDA-MB-157, -231, -453, -468,
BT-549, MCF7, T47D, SK-BR-3, HCC70, HCC1143,
and Hs578T) whose identity was authenticated with
a short tandem repeat analysis were purchased from
the American Type Culture Collection (ATCC; Manassas,
VA, USA). All cell lines were banked and passaged for less
than 6 months before use, and were maintained in a
humidified atmosphere containing 5% CO2 at 37°C in
RPMI-1640 (Thermo Fisher Scientific Inc., Waltham,
MA, USA) supplemented with 10% FBS; Welgene, Inc.,
Daegue, South Korea) and 10 μg/mL gentamicin (Cellgro,
Manassas, VA, USA).
Cell growth inhibition assay
An MTT assay was used to determine cell viability as
previously described [19]. Cells were seeded at a density
of 3 to 8 × 103 cells per well in 96-well plates and incu-
bated overnight at 37°C. The cells were then treated with
either olaparib or SAHA alone or with a combination of
olaparib and SAHA at specific concentrations for 5 d.
After treatment with the drugs, MTT solution was added
to each well and the plates were incubated for 4 h at
37°C before the medium was removed. After dissolv-
ing the resulting formazan crystals with DMSO, cell
viability was evaluated by measuring the absorbance
of each well at 540 nm with a VersaMax™ microplate
reader (Molecular Devices, Sunnyvale, CA, USA). The
combined effect of olaparib and SAHA was assessed
using Calcusyn software (Biosoft, Cambridge, UK). The
combination index (CI), which is used to evaluate the
effect of two-drug combinations, was calculated using
the Chou-Talalay method [20]. Drug synergism is de-
fined by CI values <1 while antagonism is indicated by
values >1.
Western blot analysis
Protein expression levels were measured by western
blotting as previously described [20]. Primary antibodiesagainst MRE11, caspase3, PTEN, AKT, phosphorylated
(p)-AKT, ERK, p-ERK, STAT3, p-STAT3, and LC3B were
acquired from Cell Signaling Technology (Beverley, MA,
USA). Anti-RAD51C (2H11/6) antibody was purchased
from Novus Biologicals (Littleton, CO, USA). Antibodies
against p21 and Beclin-1 were obtained from Abcam
(Cambridge, UK). Anti-p-histone H2A.X antibody (clone
JBW301) was acquired from Millipore (Billerica, MA,
USA) while anti-PARP antibody was purchased from BD
Biosciences (Bedford, MA, USA). Anti-α-tubulin anti-
body (Sigma Aldrich, St Louis, MO, USA) was used as a
control.
Cell cycle analysis
Cells treated with olaparib and/or SAHA were har-
vested, fixed in 70% ethanol, and then stored at -20°C.
The cells were dissolved in 10 μg/mL RNase A (Sigma
Aldrich) at 37°C for 20 minutes. Next, the cells were
treated with 20 μg/mL propidium iodide (Sigma Aldrich)
and the DNA contents of the cells (10,000 cells per
experimental group) were measured using a fluorescence-
activated cell sorting (FACS) Calibur flow cytometer
(BD Biosciences).
Plasmid and siRNA transfection
The pcDNA3.1-PTEN expression plasmid was obtained
from the Korea Human Gene Bank (Seoul, South Korea)
and the GFP-LC3 construct was purchased from Cell
Biolabs (San Diego, CA, USA). siRNA specific for PTEN
and nonspecific controls were purchased from Qiagen
(Hilden, Germany). Transfection was conducted using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. The sequence
of the PTEN-specific siRNA was 5′-AAGGCGTATA
CAGGAACAATA-3′. The sequence of the control
(nonspecific) siRNA was 5′-AATTCTCCGAACGTG
TCACG-3′.
Comet assays
An alkaline comet assay using a Trevigen Comet assay
kit (Trevigen, Gaithersburg, MD, USA) was performed
following the manufacturer’s protocol. Tail lengths were
measured with the Comet assay IV program (Andor
technology, Belfast, UK).
Immunofluorescence assay (GFP-LC3 localization)
Cells were plated on coverslips and transfected with the
GFP-LC3 construct. After 2 d, the cells were fixed in
3.7% paraformaldehyde and permeabilized with 0.5%
Triton X-100 in PBS (PBS-T). The coverslips were
mounted onto slides using Faramount aqueous mount-
ing medium (Dako, Glostrup, Denmark). Immunofluor-
escence was visualized using a Zeiss LSM 510 laser
scanning microscope.
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transferase dUTP nick end labeling (TUNEL) assay
Immunohistochemistry and a TUNEL assay were per-
formed as previously described [19].
In vivo study
All animal experiments were carried out in the animal
facility of Seoul National University (Seoul, South Korea)
in accordance with institutional guidelines and prior
approval from the Institutional Animal Care and Use
Committee (IACUC) committee. To measure the in vivo
activity of olaparib and/or SAHA, 35 female Balb/c athy-
mic nude 5-wk-old mice were purchased from Central
Lab Animal Inc. (Seoul, South Korea). MDA-MB-231
cells (1 × 108) were subcutaneously injected into each
mouse. After implantation of the tumor cells, the size of
the resulting tumors and body weight of each mouse
were measured. When the tumor volume reached
200 mm3, the mice were randomly divided into different
treatment groups (eight mice per group) and received
vehicle, olaparib, SAHA, or a combination of olaparib
and SAHA. All drugs were administered via oral gavages
once daily at a concentration of 30 mg/kg for 28 con-
secutive days. Tumor volume was calculated using the
following formula:
widthð Þ2  heightð Þ =2:
At the end of the measurement period, the mice were
sacrificed with CO2 and the tumors were excised for fur-
ther analysis.
Statistical analysis
Data were analyzed using SigmaPlot version 9.0 (Systat
Software Inc., San Jose, CA, USA). All results are
expressed as the mean ± standard error (SE). The
two-sided Student’s t-test was used when appropriate.
P-values <0.05 were considered statistically significant.
Results
Breast cancer cells have different levels of sensitivity to
olaparib or SAHA alone
To assess the anti-proliferative effects of olaparib and
SAHA on human breast cancer cells, 11 human breast
cancer cell lines were exposed to different concentra-
tions of olaparib or SAHA. Cell proliferation and bio-
logical activity were analyzed using an MTT assay
(Figure 1A and B). Results of this assay indicate that
breast cancer cells have a heterogeneous response to ola-
parib and SAHA regardless of subtype.
Recent studies have suggested that HDAC inhibition
leads to the downregulated expression of DNA repair
genes [14,15,18,21,22]. We therefore evaluated the
effects of HDAC inhibition by SAHA in the regulationof protein expressions that are known to effect the sensi-
tivity to PARP inhibitors, such as DNA repair factors.
SAHA markedly increased the levels of PTEN and p21.
In contrast, the expression of MRE11 and RAD51 was
downregulated (Additional file 1: Figure S1). These find-
ings imply that SAHA can affect the DNA damage
response by suppressing HRR gene expression.
Co-administration of SAHA and olaparib has a synergistic
anti-proliferative effect on some TNBC cell lines
HDAC inhibition regulates the expression levels of HRR
proteins, and some studies have shown that HDAC in-
hibition induces DNA damage [21,23]. To determine
whether SAHA can enhance the growth inhibition of
breast cancer cells by olaparib, various breast cancer cell
lines were treated with different concentrations of
SAHA or olaparib alone or in combination. IC50 values
for each treatment and the CI index were calculated
(Additional file 2: Table S1). There was a varied level of
response of the combination in TNBC cell lines. For ex-
ample, five TNBC cell lines were exposed to increasing
doses of olaparib with a fixed concentration of SAHA.
Cell growth was subsequently evaluated using an MTT
assay (Figure 2A and Additional file 3: Figure S2A). The
results showed that co-targeting the enzymatic activities
of PARP and HDACs inhibited the proliferation of
MDA-MB-157, MDA-MB-231, and HCC1143 cells
(Figure 2A) but not that of HCC70 or MDA-MB-468
cells (Additional file 3: Figure S2A).
To increase our understanding of the mechanisms
underlying the synergistic anti-proliferative effect of
SAHA and olaparib, a cell cycle analysis was conducted.
The purpose of the analysis was to determine how co-
treatment with olaparib and SAHA affects cell cycle pro-
gression. The result indicated that co-administration of
olaparib and SAHA promoted G2/M cell cycle arrest
and apoptosis in three TNBC cells with CI values <1.
However, this was not observed in the other two cells
with CI values >1, which indicated an antagonistic inter-
action (Figure 2B and Additional file 3: Figure S2B).
Co-administration of olaparib and SAHA decreases DSB
repair capacity of the sensitive TNBC cells
PARP inhibition leads to the accumulation of DNA dam-
age [19]. HDAC inhibition also promotes DNA damage
[24,25]. We hypothesized that the mechanism under-
lying the synergistic drug activity we observed may be
due to decreased DNA double-strand break (DSB) repair
capacity of TNBC cells. A comet assay was performed to
assess the DNA repair ability of TNBC cells following
PARP and HDAC inhibition. The results indicated that
co-administration of olaparib and SAHA significantly in-
creased the accumulation of DNA damage in sensitive
TNBC cells (Figure 3A) while the DNA repair profile
Figure 1 Breast cancer cell lines show a heterogeneous response to olaparib and SAHA. The growth inhibitory effects of olaparib and
suberoylanilide hydroxamic acid (SAHA) were measured with an MTT assay. The cells were treated with increasing doses of olaparib (A) and
SAHA (B) for 5 d. The percentage of surviving cells is presented in a graph with SD bars (n = 3; right). IC50 values were calculated using SigmaPlot
and are shown in the table (left).
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(Additional file 4: Figure S3). Consistent with these find-
ings, cell lines in which a synergistic effect was observed
were found to have increased levels of ɣ-H2AX expression.
This was seen in the sensitive cell lines with an ED50 value
less than 0.5 following treatment with both inhibitors
(Figure 3B). Furthermore, co-administration of olaparib and
SAHA led to a significant reduction of RAD51 foci forma-
tion and increased the number of ɣ-H2AX foci in sensitivecell lines with a combination index at ED50 value less than
0.5 (Figure 3C). These data suggest a possible mechanism
by which SAHA enhances cellular sensitivity to olaparib
through abrogation of the DNA DSB repair pathway.
PTEN expression influences the synergistic effects of
olaparib and SAHA in TNBC cells
To evaluate the effects of simultaneous PARP and
HDAC inhibition on the proliferative signaling pathway,
Figure 2 Different sensitivity levels of triple-negative breast cancer (TNBC) cells to the co-administration of poly (ADP-ribose) polymerase
(PARP) and histone deacetylase (HDAC) inhibitors. (A) The cells were exposed to increasing doses of olaparib with a fixed concentration of
suberoylanilide hydroxamic acid (SAHA) for 5 d. Cell survival was measured and the results are presented in a graph. (B) Cells were treated
with olaparib and SAHA alone or in combination at the indicated concentrations for 5 d. DNA contents of the cells were analyzed with
fluorescence-activated cell sorting. The proportion of cells undergoing the G2/M phase and apoptosis is presented in bar graphs. Columns
represent the mean of three independent experiments and are shown with error bars (± SE); *P <0.001.
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synergy but rather, antagonism was seen in two cell lines
deficient for PTEN. In addition, it is also worth noting
that treatment of cells with olaparib and SAHA synergis-
tically downregulated the levels of p-AKT and p-ERK
only in the sensitive cell lines that expressed PTEN pro-
tein (Figure 4A). We therefore hypothesized that PTEN
expression determines the anti-proliferative effects of
the PARP and HDAC inhibitor combination in sensitive
cells. To determine whether sensitivity to olaparib and
SAHA co-treatment is a direct result of PTEN defi-
ciency, we measured the IC50 values of olaparib with a
fixed concentration of SAHA in two synergistic cell lines
that were transfected with siRNA targeting PTEN or
non-specific control siRNA. Successful knockdown of
PTEN expression was validated by western blot analysis
(Figure 4B). Data from this experiment revealed that
downregulation of PTEN expression correlates with in-
creased TNBC cell resistance to the olaparib and SAHA
combination (Figure 4C).Autophagic cell death is induced by dual inhibition of
PARP and HDAC and modulated by PTEN expression
It was unclear how PTEN expression can determine the
sensitivity of TNBC cells to olaparib and SAHA. One
possible explanation is that HDAC inhibition induces
autophagic cell death through the regulation of PTEN
expression. Therefore, SAHA-induced autophagic cell
death may enhance the cytotoxic effect of PARP inhib-
ition in cell lines that express PTEN and induce autoph-
agic cell death. In order to test this possibility, we
monitored the effects of olaparib and SAHA alone or in
combination on the expression of factors associated with
both apoptotic and autophagic cell death. As shown in
Figure 5A, increased levels of LC3B and Beclin-1, two
autophagy markers, were observed after dual inhibition
of PARP and HDACs in TNBC cells that expressed
PTEN. Induction of autophagy by a combination of ola-
parib and SAHA was further confirmed by monitoring
GFP-tagged LC3 expressed in sensitive MDA-MB-231
cells and resistant MDA-MB-468 cells (Figure 5B). In
Figure 3 (See legend on next page.)
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Figure 3 Histone deacetylase (HDAC) inhibition enhances olaparib-induced DNA damage accumulation. (A) Cells were treated with
olaparib and suberoylanilide hydroxamic acid (SAHA) alone or in combination for 5 d. DNA double-strand breaks in the individual cells
were measured with a comet assay. The percentage of tail-moment was calculated and is presented in bar graphs with error bars (± SE);
*P <0.001. (B) The expression of DNA damage-responsive proteins was measured by western blot analysis following treatment with olaparib and
SAHA alone or in combination. (C) The cells were treated with 1 μmol/L olaparib and/or 1 μmol/L SAHA and the immunofluorescence analysis were
conducted with the indicated antibodies. Confocal microscopy was used to observe the signals corresponding to RAD51 (red) and ɣ-H2AX (green).
The DNA was counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). The percentage of cells containing more than 10 foci of RAD51
and ɣ-H2AX over three experiments is presented in a bar graph. At least 100 nuclei were analyzed for each experiment (right). Columns, the
mean of three independent experiments; bars, ± SE; *P <0.001.
Min et al. Breast Cancer Research  (2015) 17:33 Page 8 of 13the MDA-MB-468 cells, GFP-LC3B localization was cyto-
solic and diffuse (Figure 5B). In contrast, co-treatment
with olaparib and SAHA resulted in the re-localization of
GFP-LC3 into punctuate structures corresponding to
autophagosomes in MDA-MB-231 cells (Figure 5B).
To determine whether increased levels of autophagy
following olaparib and SAHA co-treatment is a direct
result of PTEN deficiency, changes in the expressions of
autophagy markers as well as autophagosome formation
were assessed in MDA-MB-231 cells that were trans-
fected with control or PTEN-specific siRNA. Downregu-
lation of LC3B and Beclin-1 expression was clearly
observed in the PTEN-knockdown MDA-MB-231 cells.
Conversely, LC3B and Beclin-1 expression was induced
in MDA-MB-468 cells that transiently over-expressed
PTEN (Figure 5C). Consistent with the western blot
data, co-administration of both inhibitors increased
cytosolic autophagosome formation in MDA-MB-231
cells transfected with control siRNA but not with
PTEN-specific siRNA. This appeared as a transition
from diffuse cytosolic to punctuate distribution of LC3B
(Figure 5D). PTEN protein expression was depleted by
siRNA (Figure 5D). Taken together, these data indicate
that the expression of PTEN plays an important role in
determining the combined effect of olaparib and SAHA
in TNBC cells. Moreover, the synergistic effect of ola-
parib and SAHA is associated with increased levels of
both apoptosis and autophagy, two processes that are
regulated by PTEN.
Co-treatment with olaparib and SAHA significantly
inhibits cell proliferation and induces both apoptosis and
autophagic cell death in an in vivo mouse model
To confirm our in vitro findings in an in vivo setting, we
used a mouse xenograft model injected with MDA-MB-
231 human breast cancer cells. Co-treatment with olaparib
and SAHA significantly delayed tumor growth not only
during treatment but also after treatment had ceased
(Figure 6A). There were no signs of toxicity in the mice
undergoing extended treatment (Figure 6B). Tumor tis-
sues from the mice treated with both olaparib and SAHA
showed lower Ki-67 expression, suggesting a reduced
proliferation ability compared to the tumor tissues from
mice treated with a single agent alone. This effect wasassociated with increased apoptosis observed with a
TUNEL assay (Figure 6C). We also observed that the ex-
pression of proteins related to proliferation (such as AKT
and ERK) was reduced. Additionally, the levels of PARP
cleavage (associated with apoptosis) as well as LC3B and
Beclin-1 (that affect the induction of autophagy) were
clearly increased following co-treatment with olaparib and
SAHA (Figure 6D). This experiment demonstrated that
co-treatment with olaparib and SAHA significantly in-
hibits cell proliferation and induces both apoptosis and
autophagic cell death in an in vivo mouse model.
Discussion
Genomic instability is a key feature of cancer develop-
ment, and DNA repair pathways have a significant im-
pact on genomic stability. Defects in genome stability
increase the sensitivity of cells to DNA damaging agents
and provide an Achilles heel for cancer therapeutics
[26,27]. Olaparib, a PARP inhibitor that targets defects
in the DNA repair pathway, has produced promising
results in TNBC patients with BRCA deficiencies or
BRCAness. However, the population of BRCAness in
TNBC patients is reported to be limited, so many efforts
have been made to extend the usage of PARP inhibitors
[19,28-30]. Various reports have demonstrated that com-
promised HRR activity sensitizes BRCA-proficient can-
cers to PARP inhibitors [10,19,29]. Additionally, PARP
inhibitors are a useful therapeutic strategy treating cases
of cancer with a variety of HRR pathway deficiencies.
Recent studies have suggested that the inhibition of
HDAC activity impedes the HRR pathway, resulting in
increased cellular sensitivity to DNA-damaging agents
[13,31]. Thus, HDAC inhibition leads to the creation
of cells that may mimic an HRR-deficient phenotype,
resulting in increased PARP inhibitor sensitivity [31,32].
In the present study, we evaluated the synergistic ef-
fects of simultaneous PARP and HDAC inhibition on
proliferation and cell cycle progression in sensitive
TNBC cell lines. We also assessed the synergistic effects
of PARP and HDAC co-targeting in TNBC cells. Our
findings indicated that these effects are attributable to
decreased DSB repair capacity due to HDAC inhibition,
thereby resulting in DNA damage accumulation induced
by PARP inhibition. We also discovered that TNBC cells
Figure 4 Phosphatase and tensin homolog (PTEN) expression affects the combined effect of olaparib and suberoylanilide hydroxamic
acid (SAHA) in triple-negative breast cancer (TNBC) cells. (A) The expression levels of proliferative signaling pathway proteins in TNBC cells
were analyzed by western blotting following drug treatment. (B) Transfection efficacy was verified by western blot analysis with anti-PTEN,
anti-phosphorylated (p)-AKT, and anti-α-tubulin (as a loading control) antibodies. (C) PTEN silencing decreased cellular sensitivity to dual inhibition
by the poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) inhibitors. The cells were transfected with nonspecific control or
PTEN-specific siRNA, and then exposed to increasing concentrations of olaparib with a fixed concentration of SAHA for 5 d. IC50 values are
presented in bar graphs with error bars (n = 3); *P <0.001. CI, combination index.
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plus SAHA.
Interestingly, TNBC cells exhibiting synergistic re-
sponses to the olaparib-SAHA combination had a greater
decrease of proliferative pathway activity observed as AKTand ERK phosphorylation. Our findings support the hy-
pothesis that the synergistic effects on TNBC cells depend
on PTEN expression.
PTEN is a well known target of HDACs. Not surpris-
ingly, HDAC inhibition leads to the upregulation of PTEN
Figure 5 Phosphatase and tensin homolog (PTEN) expression increases the synergistic effect of olaparib with suberoylanilide
hydroxamic acid (SAHA) due to the induction of autophagic cell death. (A) The cells were treated with olaparib and SAHA alone or in
combination for 5 d. The expression levels of apoptosis and autophagy mediators were then examined by western blotting. (B) Induction of
autophagy was confirmed by monitoring GFP-tagged LC3 expression in MDA-MB-231 (left) and MDA-MB-468 (right) cells following exposure to
olaparib, SAHA, or both inhibitors. (C) MDA-MB-468 cells were transfected with siRNA targeting PTEN or the negative control. Additionally, the cells
were transfected with an empty vector or one encoding PTEN. After 2 d the expression of autophagy markers was evaluated using immunoblotting.
(D) Translocation of GFP-tagged LC3 in MDA-MB-231 cells transfected with control or PTEN-specific siRNA was examined by confocal microscopy
(top). siRNA-mediated reduction of PTEN expression was confirmed by western blotting (bottom). CI, combination index.
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been suggested as a marker that can help predict positive
responses to PARP inhibitors [33], the sensitivity of PARP
inhibition is not associated with PTEN deficiency in at
least two TNBC cell lines (HCC70 and MDA-MB-468)
that we evaluated. Rather, PTEN deficiency appears to in-
duce resistance to the combination effect of simultaneous
inhibition of PARP and HDACs in TNBC cells. Activationof PTEN along with decreased AKT and ERK phosphoryl-
ation by treatment with olaparib plus SAHA in the
present study suggested that proliferative signaling path-
ways are modulated by the combination of olaparib and
SAHA. PTEN activation blocks cell cycle progression,
thereby suppressing tumor formation and progression. In
addition, PTEN is crucial for regulating and maintaining
PI3K/AKT signaling [34]. Loss of PTEN function mainly
Figure 6 Suberoylanilide hydroxamic acid (SAHA) enhances the anti-tumor effects of olaparib in an MDA-MB-231 xenograft model.
(A) A mouse xenograft model with MDA-MB-231 human breast cancer cells was established. The mice were treated with 30 mg/kg olaparib (n = 8),
30 mg/kg SAHA (n = 8), 30 mg/kg olaparib plus 30 mg/kg SAHA (n = 8), or vehicle alone (n = 8) daily for 28 d. Tumor volumes for each mouse were
measured and are presented in a graph with the SD. Olaparib plus SAHA significantly inhibited tumor growth in a MDA-MB-231 mouse xenograft
model (*P <0.001). (B) Changes in mouse body weight were measured to estimate the toxicity of each treatment. (C) The tumors were removed
from the mice 10 d after drug treatment ended, and immunohistochemical staining for Ki-67 along with a TUNEL assay were conducted. Representative
images from this study are presented with scale bars representing 25 μM (400× magnification). Arrows indicate positive staining. (D) Total cell
proteins were extracted from tissues and the expression of molecules associated with proliferation, apoptosis, and autophagy were evaluated
with western blotting.
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frequently observed in breast cancer. The PI3K/AKT
pathway represents a mechanism of resistance to cancer
therapeutic agents as well as PARP inhibitors [34]. There-
fore, upregulated PTEN expression induced by HDAC in-
hibition would enhance the cytotoxic effect of PARP
inhibitors in PARP inhibitor-resistant breast cancer cells.
This would be a rational argument for administering a
combination regimen of olaparib plus SAHA for treating
TNBC.
Another novel finding from the current investigation
is that PTEN expression can determine the combined
effects via the regulation of autophagic cell death. Induc-
tion of autophagy was clearly observed in TNBC cellsexpressing PTEN in which synergism between olaparib
and SAHA was observed. Autophagy is a ubiquitous
process of recycling cellular compartments and is mainly
considered a cytoprotective response to metabolic
stresses [35-38]. While autophagy is characterized as
a mediator of cell death in the presence of chronic
stress, it is unclear under which conditions autophagy
promotes cell death or cell survival. Additionally, the
interaction between autophagy and apoptosis is not
well-established. Nevertheless, the effect of HDAC inhib-
ition on autophagy has been studied in several types of
cancers although many questions remain as to whether
the induction of autophagy is cytoprotective or cytotoxic
for cancer cells [38]. In general, many studies in the field
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anism of autophagy in tumor cells [37-39]. Subsequently,
autophagy suppression has been suggested to be a way
to improve the therapeutic benefit of cancer treatments.
It has also been hypothesized that autophagy induced by
HDAC inhibition enhances the ability of cancer cells to
escape cell death. However, we found that increased
levels of autophagy correlated with increased cell death
following olaparib and SAHA combination treatment.
Based on data from the present study, we suggest a
mechanism by which HDAC inhibition following SAHA
treatment increases PTEN expression, leading to the
downregulation of proliferative signaling pathways in-
cluding the AKT/mTOR cascade and an associated in-
creased sensitivity to PARP inhibitor-induced apoptosis.
In addition, HDAC inhibition contributes to autophagy
induction that also results in increased cancer cell death.
In summary, findings from the current investigation
demonstrated that TNBC cells have different responses to
olaparib and SAHA alone or in combination. Combination
therapy with selective PARP and HDAC inhibitors may be
an effective strategy for treating cases of TNBC with func-
tional PTEN expression. The combination of PARP and
HDAC inhibitors significantly promoted growth inhibition
as a result of proliferative signaling pathway suppression,
and also led the accumulation of DNA damage. Our data
suggest that the combination of PARP and HDAC inhibi-
tors also induces both apoptotic and autophagic cell death,
which increases the cytotoxic effects of the inhibitors.
These combined effects resulting in cell death are regulated
by PTEN expression in TNBC cells. Results from our in-
vestigation indicate that olaparib plus SAHA could be a
novel strategy for treating cases of TNBC with PTEN ex-
pression. In light of these findings, the combination of
PARP and HDAC inhibitors may merit further clinical
evaluation in patients suffering from TNBC.Conclusion
Our data show that a combination of olaparib with
SAHA exerted synergistic effects against TNBC cells
that expressed PTEN. This combination benefit was also
observed in vivo using an MDA-MB-231 xenograft
model and the mechanism underlying the combined
effects we observed was further elucidated. Our data
provide a strong rationale for using a combination of
olaparib with SAHA to treat TNBC patients, especially
cases with functional PTEN expression.Additional files
Additional file 1: Figure S1. Effects of histone deacetylase (HDAC)
inhibition on protein expression in triple-negative breast cancer (TNBC)
cell lines. The cells were exposed to increasing doses of suberoylanilidehydroxamic acid (SAHA) for 3 d. The expression levels of DNA repair
molecules were then analyzed by western blotting.
Additional file 2: Table S1. Combined effects of olaparib and SAHA on
human breast cancer cell lines. The cells were treated with olaparib and
suberoylanilide hydroxamic acid (SAHA) alone or in combination for 5 d.
Cell viability was then calculated. IC50 values for each treatment and the
combination index (CI) were calculated. The results are presented in
the table.
Additional file 3: Figure S2. Combination of olaparib and suberoylanilide
hydroxamic acid (SAHA) suppresses proliferation and cell cycle progression in
insensitive triple-negative breast cancer (TNBC) cells. (A) An MTT cell viability
assay was conducted to compare responses of the cells to increasing
concentrations of olaparib with a fixed concentration of SAHA for 5 d.
(B) The percentage of cells undergoing apoptosis and G2/M arrest
following 5 d of treatment was determined by fluorescence-activated
cell sorting (FACS).
Additional file 4: Figure S3. Dual inhibition of poly (ADP-ribose)
polymerase (PARP) and histone deacetylases (HDACs) does not lead to
the accumulation of DNA damage in insensitive triple-negative breast
cancer (TNBC) cells. The levels of DNA double-strand breaks were measured
with a comet assay. The percentage of tail-moment was calculated and is
shown in bar graphs with error bars (± standard error).
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